Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 First-in-Human Clinical Trial in Healthy Participants and Patients With C3-Glomerulopathy to Assess Safety, Tolerability, and Pharmacokinetics of CPV-104

NCT07483827 is registered in ClinicalTrials.gov with eleva GmbH as lead sponsor.

NCT NCT07483827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07483827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 First-in-Human Clinical Trial in Healthy Participants and Patients With C3-Glomerulopathy to Assess Safety, Tolerability, and Pharmacokinetics of CPV-104
Lead sponsor
eleva GmbH
Phase
Phase 1
Overall status
Recruiting
Start date
June 26, 2025
Completion date
November 30, 2026
Enrollment
39 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

c3 glomerulopathy (c3g), healthy adult participants